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Abstract  
The COVID-19 pandemic is now an international concern. COVID-19 is first reported in Wuhan, China on 31 
December 2019 and affects different people in different ways. Evidence suggests that people with underlying 
disease are at higher risk for more severe disease. People with diabetes are not only more likely than the 
general population to have COVID-19 but also they are among those high-risk categories that can have serious 
illness if they get the virus. 
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CONTEXT
The COVID-19 pandemic, also identified as the 
coronavirus pandemic, caused by the severe acute 
respiratory syndrome coronavirus (SARS-CoV-2), 
is now suffering the world. 'CO' stands for corona, 
'VI' for virus, and 'D' for disease. COVID-19 is first 
reported in Wuhan, China on 31 December 2019. 
Coronaviruses (CoVs), enveloped positive-sense 
Ribonucleic acid (RNA) viruses characterized by a 
distinctive replication strategy (1). According 
to the report of the European Centre for Disease 
Prevention and Control as of 29 March 2020, there 
have been 4,223,047 reported cases of COVID-19 
worldwide, including 291,519 deaths. COVID-19 
affects different people in different ways. Most 
infected people will develop mild to moderate 
illness and recover without hospitalization. This 
disease has an incubation period of about 2-14 
days and 1–2 weeks of symptomatic disease. In the 
symptomatic stage, it has a wide variety of 
symptoms including fever, cough, sore throat, 
headaches, and in severe form; respiratory 
problems such as viral pneumonia, respiratory 
failure, and multi-organ dysfunction (2). 
COVID-19 affects all age groups. However, 
evidences to date suggest that two groups of people 
are at higher risk of developing more severe 
disease, including older adults (i.e.  people over 60 
years old); and people with underlying diseases 
such as cardiovascular diseases, diabetes, chronic 
pulmonary disease, and malignancy (3). More than 
425 million people worldwide have diabetes. 
People with diabetes are not only more likely than 
the general population to have COVID-19 but also  
they are amongst those high-risk categories that 
can have serious illness if affected by virus (4). 
However, nowadays a dearth of data still exists on 
the management of diabetes during the COVID-19 
pandemic. 
EVIDENCE ACQUISITION 
The main keywords, i.e. COVID-19, coronavirus, 
SARS-CoV-2, diabetes and, clinical presentation of 
COVID-19 were used to search in the scientific 
databases. The authors reviewed the literatures 
published, using Medline, Scopus, Cochrane 
database for systematic reviews and Scopus, Web 
of Science, PubMed, and Google scholar search 
engines. All types of articles, such as reviews, 
originals, letters, and etc., were included in the 
study.  The most relevant articles were studied and 
summarized.  Finally, the best articles related to the 
context of the subject were selected and required 
information were extracted. 
RESULTS 
For better understanding the findings were 
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categorized and discussed in reply to 10 questions, 
based on current knowledge 
DISCUSSION 
1) Are people with diabetes at increased risk to 
get COVID-19? 
Individuals with diabetes are at risk of infections 
(5). But based on current knowledge people with 
diabetes are not only more prone to have COVID-
19 than the other people but also they are more 
susceptible to get more severe disease. They are at 
an increased risk of getting acute respiratory 
distress syndrome (ARDS) and increased mortality. 
Also, the symptoms and complications of COVID-19 
are more common in people with diabetes than in 
the general population (6). 
2) What are the factors associated with the 
severity of covid19 in subject with diabetes? 
In certain cases, patients with diabetes are at 
higher risk to get serious complications from 
COVID-19. For example, they are at increased risk 
of getting very sick if their blood sugar is not 
controlled (7). Aging, history of cardiovascular 
disease, chronic lung and kidney disease, and 
hypertension are associated with a higher chance 
of COVID-19 severity. Beside them; ethnicity, body 
mass index, and some medication can play a role in 
the severity of COVID-19. Therefore special 
attention should be paid to underlying diseases in 
patients with diabetes, especially among the 
elderly (8). Among biochemical biomarkers, the 
presence of lymphopenia and an increase in 
interleukin 6 and CRP are associated with severe 
disease (8). 
3) Are the chances of developing COVID-19 
different in type 1 and type 2 diabetes? 
There is no enough evidence to differentiate 
between the risk of COVID-19 and types of 
diabetes. But we do know that these two types of 
diabetes are different in terms of age, the onset of 
complications, and treatment options. Therefore, 
people with diabetes (regardless of diabetes type) 
should be take the necessary precautions to 
prevent COVID-19 (8). 
4) What is the reason for worsening the 
outcome of covid 19 disease in patients with 
diabetes? 
COVID-19 in diabetic subject probably create 
higher stress situations, with the greater secretion 
of counter-regulatory hormones, it can trigger to 
high blood glucose level and fluctuation in the 
blood glucose. The reasons for the worsened 
outcomes for those with hyperglycemia aren’t 
understood. Beside, Hypoglycemia increases 
cardiovascular mortality in people with diabetes 
possibly by mobilizing pro-inflammatory 
monocytes and increasing platelet reactivity (8). 
Now, we don’t have enough information about the 
occurrence of inflammatory and immune 
responses in patients with diabetes, furthermore, 
there is little evidence for changing the virulence of 
the COVID-19 by hyper or hypoglycemia or effects 
of the virus on insulin secretion or glycemic 
control. Various mechanisms have been proposed 
to increase the susceptibility of patient with 
diabetes to more severe COVID-19. Diabetes is an 
inflammatory disease that causes the production of  
advanced glycation End-products (AGEs) and 
inflammatory factors by increasing the 
glycosylation. Uncontrolled diabetes is also 
associated with inhibition of lymphocyte 
proliferation and neutrophil dysfunction. 
Angiotensin 2 converter enzyme is one of the main 
receptors for SARS-CoV (8). This enzyme acts as a 
receptor for the virus to enter the host lung 
pneumocyte cells and causes lung damage (9). 
Pancreatic cells are one of the receptor sites; SARS-
CoV can damage the pancreas and eventually make 
the disease worse. Reduction in viral clearance and 
insulin resistance are other mechanisms involved 
in the disease severity in diabetic patients (7). This 
inflammatory response possibly could explain 
differences in susceptibility to more severe 
infections with worse consequences in diabetes.  
5) What preventative measures can patient 
with diabetes take against the coronavirus 
disease? 
Based on our current understanding people with 
diabetes are at high risk for developing more 
severe COVID-19 especially when they have an 
underlying condition. The first point is that if a 
person with type-2 diabetes finds any signs of 
COVID-19 symptoms, they should consult with 
their doctor about their medication.  Secondly, like 
everyone else in the community, diabetics need to 
take the necessary precautions to prevent COVID-
19. In particular, to prevent COVID-19 in a patient 
with diabetes, it is recommended to control their 
glycemic, performing more physical activity and, 
have accurate monitoring of blood sugar to reduce 
the risk of complications from COVID-19 (10).  
6) Is it necessary to change the treatment of 
diabetic patients if hydroxychloroquine is 
started? 
Hydroxychloroquine is one of the drugs used in 
COVID-19 (11). It can reduce insulin post receptor 
clearance, facilitate glucose transfer by insulin and, 
suppress inflammatory biomarkers (12). 
Therefore, it can cause hypoglycemia and required 
dose adjustment in diabetic patients especially if 
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they have increased risk for hypoglycemia. The 
safely uses of hydroxychloroquine in diabetic 
patients with COVID-19 improve blood sugar, 
decreased requirements insulin , and decreased 
HbA1c levels (11). 
7) Are people with diabetes more prone to DKA 
if they get COVID-19? 
Like other viral infections, diabetics with COVID-19 
are prone to ketoacidosis commonly experienced 
by people with type-1 diabetes (13). Diabetic 
ketoacidosis (DKA) can complicate fluid and 
electrolyte management which is important in 
managing infection. 
8) How is the management of diabetic patients 
with COVID-19 infection in outpatient 
setting? 
Healthcare workers should sensitize the subjects 
with diabetes for the importance of optimal 
metabolic control and current diabetic treatment. 
They don’t discontinue their treatment without 
physician advice. It is important to know there is no 
need to prophylactically discontinue diabetic 
treatment for out-patients COVID-19 with diabetes. 
For better care of diabetes patients using virtual 
care is recommended (14).  
9) How is the management of diabetic patients 
with COVID-19 infection in inpatient setting? 
First, every patient hospitalized with a COVID-19 
infection needs to be screened for new onset 
diabetes. Afterward, its necessary to optimize  
glycemic control in an attempt to reduce the risk of 
severe COVID-19 disease. In the case of severe 
COVID-19 disease, insulin therapy should be 
started. It is important to check the potassium 
balance carefully following the initiation of insulin. 
Because hypokalemia is common in COVID-19 
(possibly due to association with 
hyperaldosteronism induced by high 
concentrations of angiotensin-2) and it can be 
exacerbated if insulin is started (13).  
10) Should oral hypoglycemic agent in diabetics 
be changed in the event of a COVID-19 
infection? 
Careful glycemic control is necessary to lessen the 
risk of severe COVID-19 disease. The general rule 
for treating diabetic patients in the context of 
COVID-19 is that there is no need to change 
medication if they have a mild illness and are 
treated on an outpatient basis. In diabetic patients 
with severe symptoms of COVID-19, treatment 
with metformin and sodium-glucose co-
transporter-2 (SGLT2) inhibitors should be 
discontinued due to the possibility of lactic acidosis 
and euglycaemic ketoacidosis respectively. 
Basically, if oral medication is stopped, the 
alternative treatment would be  insulin therapy 
(15). 
CONCLUSIONS 
COVID-19 has been rapidly expanding since its 
inception in Wuhan. Diabetes is one of the risk 
factors for the increased severity and augmented 
mortality in patients with COVID-19. Timely 
diagnosis and proper management of the disease in 
people with diabetes is  associated with a better 
control. The assosiattion between diabetes and 
COVID-19 is largely unknown. Our information 
about COVID-19 is increasing day by day. Recent 
data is mostly based on both assumption and 
factual. However, these data provide a basis for 
future research on the pathophysiological 
mechanism of COVID-19 in patients with diabetes. 
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